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Abstract
Neuroblastoma (NB) pathogenesis has been reported to be closely associated with numerous genetic alterations. However,
underlying DNA methylation patterns have not been extensively studied in this developmental malignancy. Here, we
generated microarray-based DNA methylation profiles of primary neuroblastic tumors. Stringent supervised differential
methylation analyses allowed us to identify epigenetic changes characteristic for NB tumors as well as for clinical and
biological subtypes of NB. We observed that gene-specific loss of DNA methylation is more prevalent than promoter
hypermethylation. Remarkably, such hypomethylation affected cancer-related biological functions and genes relevant to NB
pathogenesis such as CCND1, SPRR3, BTC, EGF and FGF6. In particular, differential methylation in CCND1 affected mostly an
evolutionary conserved functionally relevant 39 untranslated region, suggesting that hypomethylation outside promoter
regions may play a role in NB pathogenesis. Hypermethylation targeted genes involved in cell development and
proliferation such as RASSF1A, POU2F2 or HOXD3, among others. The results derived from this study provide new candidate
epigenetic biomarkers associated with NB as well as insights into the molecular pathogenesis of this tumor, which involves a
marked gene-specific hypomethylation.
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Introduction
Neuroblastoma (NB), the most common extracranial tumor of
childhood, is a complex developmental malignancy characterized
by numerous biologically significant genetic alterations that are
intimately associated with the clinical outcome of patients [1]. In
addition to genetic changes, the complex and heterogeneous
clinical evolution of NB greatly depends on patient’s age at
diagnosis, as well as clinical stage and histopathologic features of
the tumor [1].
Altered DNA methylation patterns have been widely reported
to be a critical factor in cancer development and progression. In
particular, regional DNA hypermethylation (hyperM) of CpG
islands in promoter regions of tumor suppressor genes as well as
global hypomethylation (hypoM) affecting DNA repeats are
considered to be the most frequent cancer-related epigenetic
changes [2,3]. So far, most studies have focused their attention on
the role and mechanisms of promoter hyperM, since loss of global
DNA methylation was believed to affect DNA repeats and to be
mainly involved in structural-nuclear functions such as chromo-
somal instability [2].
Although the genomic profile of NB is well-characterized, DNA
methylation changes have not been extensively studied in these
tumors. Several genes have been reported as being methylated in
NB [4–9], nevertheless the genome-wide DNA methylation
pattern of NB is still greatly unknown. The aim of the present
study was to investigate the pattern of epigenetic changes in NB at
the genome-wide level using DNA methylation-specific micro-
arrays. Besides identifying changes globally associated with NB, we
characterized DNA methylation patterns associated with distinct
clinical and biological subtypes of the disease. Interestingly, we
observed that gene-specific loss of DNA methylation is more
prevalent than promoter hyperM. Such hypoM affected cancer-
related biological functions and genes relevant to NB pathogenesis
such as CCND1 [10].
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Materials and Methods
Patients and samples
A total of 25 primary neuroblastic tumors (NT) including 22
NBs, 2 ganglioneuromas (GN) and 1 ganglioneuroblastoma (GNB)
were used for genome wide methylation analysis. Additionally, an
independent cohort of 13 NBs and 2 GN was used for bisulfite
pyrosequencing, mRNA gene expression and DNA copy number
variation analyses (Table 1 and Table S1A). GN and GNB as well
as normal human fetal brain (FB) and adrenal gland (AG) tissues
were used as reference samples. NB risk assessment was defined by
the International Neuroblastoma Staging System (INSS) [11].
Tumor samples were assessed by a pathologist (M.S.), only tumors
with .70% viable tumor cell content were included in the study.
DNA was isolated from snap-frozen samples using Cell Lysis
Solution (Promega, USA) and proteinase K (Sigma, USA)
following manufacturers’ protocols.
Ethics statement: The study was approved by the Institutional
Research Ethics Committee (Comité Ético de Investigación
Clı́nica, Fundación Sant Joan de Déu – CEIC-FSJD). Patients/
parents/guardians signed an informed consent before collection of
samples.
Genome-wide DNA methylation profiling
DNA methylation profiling was performed using the Infinium
HumanMethylation27 BeadChip (Illumina, USA). Genomic DNA
bisulfite conversion and hybridization to the platform was
performed at the Human Genotyping Unit at the Spanish
National Cancer Center (CEGEN-CNIO, Madrid, Spain), as
previously described. Data were analyzed using the BeadStudio
software (version 3, Illumina Inc, USA) [12,13]. For each CpG site
we calculated the beta-value (bvalue), which is a quantitative
measure of DNA methylation levels ranging from 0 for completely
unmethylated to 1 for completely methylated cytosines. Possible
sources of biological and technical biases that could affect our
results such as gender-specific and low quality CpGs were
excluded from the study [14–16]. Methylation microarray data
have been deposited at Gene Expression Omnibus data repository
(GSE39626).
Differential DNA methylation analysis
Since there is no consensus strategy for differential methylation
analysis, we used three different approaches. First, CpG sites were
categorized as hyperM when bvalues were ,0.25 in the reference
samples and .0.75 in at least 10% of NB samples, and hypoM
when bvalues were .0.75 in the reference samples and ,0.25 in
at least 10% of NB samples. Second, differential methylation was
defined as mean bvalues between NB and reference samples
showing an absolute difference greater than 0.25 [17]. Finally, an
unpaired t-test was performed using Step Down Permutation
(SDP) [18] and False Discovery Rate (FDR) analyses [19]. Venn
diagrams were used to compare lists of differentially methylated
CpGs (http://www.pangloss.com/seidel/Protocols/venn.cgi) and
only those concomitantly identified by all three classification
criteria were defined as differentially methylated.
Hierarchical clustering and principal component analysis
Unsupervised and supervised agglomerative hierarchical clus-
tering were performed using the Cluster Analysis tool from Bead
Studio (version 3, Illumina Inc, USA). Principal Component
Analysis (PCA) was performed with R (www.r-project.org) using
the FactoMineR package available through Bioconductor.
Bisulfite pyrosequencing
To validate DNA methylation data, bisulfite pyrosequencing
(BPS) analysis was performed as previously described [20]. Briefly,
genomic DNA was bisulfite converted using EpiTect Plus Bisulfite
Conversion Kit (Qiagen, Hilden, Germany) according to manu-
facturer’s instructions. A subsequent PCR amplification was
performed using biotinylated primers (Table S1B). Pyrosequencing
and data analysis were performed with the pyrosequencer analyzer
PyroMark Q96 (Qiagen, Hilden, Germany) according to manu-
facturer’s instructions.
Gene expression analysis
To assess expression levels of differentially methylated genes,
publicly-available expression microarray data sets [21–23] with
representative NB tumor spectra were analyzed. Raw data was
normalized to a z-score transformation. Unpaired t-test analysis
adjusted by SDP and FDR was performed. Genes with a
Table 1. Patients’ clinical and biological characteristics.





Stage 1–3 11 (50) 5 (38,5)
Stage 4 7 (31,8) 6 (46,2)
Stage 4S 4 (18,2) 2 (15,3)
MYCN status, n (%)
Amplified 5 (22,7) 10 (76,9)
Non-amplified 16 (72,8) 3 (23,1)
Undetermined 1 (4,5) 0
The NB cohort used for genome-wide methylation analysis (Methylation Array Sample Set) as well as the NB cohort used for bisulfite pyrosequencing, mRNA gene
expression and DNA copy number variation analyses (Independent Sample Set) are reported in the table.
doi:10.1371/journal.pone.0048401.t001
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statistically significant differential expression (p,0.01), z-score .1
in .50% of samples, were considered differentially expressed.
For candidate genes, total RNA isolation and gene expression
quantification was performed for 10 cases included in the
methylation array and an independent set of 13 NB samples
using quantitative real time polymerase chain reaction (qRT-PCR)
as previously described [22] (Table S1B).
Bioinformatic annotation of differentially methylated
genes
The Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.7 (http://david.abcc.ncifcrf.gov/) was used
for gene-annotation enrichment analysis and biological pathway
mapping [24]. Probability (Benjamini-Hochberg correction) lower
than 0.05 was considered statistically significant.
Differentially methylated genes were classified according to their
chromosomal localization. Probability distribution analysis was
performed to determine potential chromosome enrichment. P-
value,0.05 was considered statistically significant.
Promoter classification of differentially methylated genes into
promoters with high (HCP), intermediate (ICP), low (LCP) and
mixed CpG content, as well as the identification of Polycomb
(PcG) target genes was performed as previously reported [14].
Hypergeometric probability distribution analysis with a prob-
ability cut-off ,0.05, was performed to determine hyperM or
hypoM chromosome enrichment and to determine promoter type
and PcG-mark enrichment in differentially methylated genes.
Analyses were performed with SPSS version 15.0 (SPSS, Inc,
Chicago, IL).
Results
DNA methylation profiling and identification of
differentially methylated genes in NB
In order to investigate the pattern of DNA methylation in NB,
we analyzed 22 primary NB tumors using the Infinium
HumanMethylation27 BeadChip microarray. Two GN, 1 GNB,
as well as, normal human FB and AG tissues were used as
reference samples to identify differentially methylated genes
specific for NB.
We initially performed a quality control of the data obtained
from the microarray analysis and excluded 3337 gender-specific
and low quality CpGs. Additionally, one NB sample (NT18, Table
S1A) was excluded because of poor detection p-values.
Unsupervised Principal Component Analysis (PCA) performed
on all the samples included in the study, showed that NBs display a
clearly distinct DNA methylation profile as compared to normal
reference samples (FB and AG) and the clinically less aggressive
GNB and benign GN (Figure 1A), being these two entities
epigenetically undistinguishable from normal reference samples.
In order to identify differentially methylated genes in NB,
supervised analyses were performed using independently three
different reference samples (FB, AG and 2 GN with 1 GNB). By
comparing gene lists generated by these analyses we were able to
identify a common set of 351 genes, being 23 hyperM and 328
hypoM, in NB (Figure 1B, Table S2A). This set of genes will be
hereafter referred as NB-specific genes. We then performed a
supervised hierarchical cluster and a PCA using the hyperM and
hypoM gene sets separately. Remarkably, the DNA methylation
pattern of hyperM genes allowed us to differentiate NBs with
diverse MYCN amplification status. Interestingly, hypoM genes
segregated NBs by their age at diagnosis, clustering those with 5 or
more years separately from younger patients (Figure 1C and 1D).
The NB-specific genes were ranked according to the percentage
of samples found differentially methylated and the level of bvalue
changes. The most clearly hyperM genes in our series were EMP1,
RASSF1A, ACTC, GNG12, HOXD3, PAMR1, IL17RC, CARD11,
POU2F2 and P2RY6 (Table S2B). Among these, RASSF1A and
POU2F2 have previously been described methylated in NB tumors
and cell lines. Here, both genes showed clearly increased
methylation levels in $80% of the NB samples, which is consistent
with prior reports [5,7,25]. Besides, to our knowledge only
HOXD3 has previously been described hyperM in cancer,
specifically in prostate carcinoma [26,27].
Applying the same strategy, 69 genes were clearly hypoM in NB
(Table S2B). Notably, among these we identified CCND1. This
gene has been reported to be highly expressed in a significant
portion (.75%) of NB tumors and cell lines [10,28]. The 17 CpGs
analyzed across the length of the CCND1 locus revealed a complex
epigenetic pattern in NB cases and control samples (Figure 2A). In
NB, we observed a reduction of DNA methylation levels at 12 of
17 CpG sites and a significant hypomethylation, using stringent
criteria, only at two CpGs (Target IDs cg04717045 and
cg02723533). Unexpectedly, DNA methylation loss was observed
outside the 59 region of CCND1, which was unmethylated in NB
cases and control samples. Hypomethylation within the gene-body
was not considered significant due to epigenetic heterogeneity in
the reference samples (Figure 2A). The 39 untranslated region (39-
UTR), in contrast, was consistently methylated in reference
samples and hypomethylated in a large fraction of NBs. At the
two significantly hypoM sites, 17 of 21 NB lose methylation as
compared to all the reference samples (bvalue .0.90), being 11 of
them markedly hypoM (Figure 2A).
DNA methylation changes in clinically and biologically
relevant NB subgroups
A supervised approach was used to analyze differential DNA
methylation profiles between clinical and biologically relevant NB
subgroups.
High-risk (HR) NBs (n = 9), defined as stage 4 and MYCN
amplified (MYCN A) tumors, were compared with low-risk (LR)
NBs (n = 8), which include stage 1 to 3 MYCN non-amplified
(MYCN NA) tumors. A total of 19 clearly differentially methylated
genes were identified. Five genes were hyperM in HR with respect
to LR NB and reference samples, whereas no hypoM gene was
observed in this clinical subgroup. In contrast, hyperM was not
observed in LR NBs whilst 14 genes exhibited de novo loss of
methylation in this clinically favorable subgroup (Table S2C).
We next compared the two clinically relevant metastatic NB
subgroups, i.e. stage 4 (n = 6) and stage 4S (n = 4) NBs. We
identified a total of 9 differentially methylated genes. Of these, 2
genes were hyperM in at least 3 of 4 stage 4S NBs and no hyperM
was detected in stage 4 NBs. With regard to hypoM, 5 and 2 genes
were observed in stage 4S and 4 NBs, respectively (Table S2C).
Comparing MYCN A (n = 5) and NA (n = 15) tumors, we
identified 23 differentially methylated genes (7 hyperM and 16
hypoM) in MYCN amplified with respect to non-amplified tumors
and reference samples (Table S2C).
Finally, we compared NBs based on patient’s age at diagnosis
using the clinically-established 18 month age cut-off, i.e. ,18
months (n = 11) and $18 months (n = 10). According to our
selection criteria, no consistently differentially methylated genes
were identified, most likely due to the high heterogeneity in both
subgroups. Based on the supervised PCA analysis shown in
Figure 1D, we observed that patients with 5 or more years of age
segregated separately from the younger patients, suggesting
different underlying methylation patterns. A supervised analysis
DNA Methylation Profiling in Neuroblastoma
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was thus performed using two age cut-offs, 18 months and 5 years
(i.e. 0 to ,18 months (n = 12), $18months to ,5 years (n = 4), $5
years (n = 5)). Differences between the methylation patterns of the
three age subgroups were observed. However, methylation was
heterogeneous in patients younger than 5 years, but clearly distinct
from the older NB patients (Table S2C). Applying only a 5 year
age cut-off (,5 years, n = 16 and $5 years, n = 5), we identified a
clear DNA methylation pattern characterized by a set of genes
with a consistent loss of DNA methylation in patients younger than
5 years of age compared with the older patients, the latter being
similar to reference samples (Table S2C).
Technical and clinical validation of candidate genes by
pyrosequencing
DNA bisulfite pyrosequencing of 3 NB-specific candidate genes
(EMP1, GNG12 and CCND1) as well as of EPSTI1, which is
differentially methylated in clinically relevant NB subgroups, was
performed to validate DNA methylation array data. Two NB
tumors included in the microarray as well as an independent
cohort of 13 NB and 2 GN samples were used for this aim. First,
the degree of correlation between microarray DNA methylation
and BPS data was tested and found to be significantly high
(r = 0.958, p,0.001) (Figure S1).
Consistent with the array results, EMP1 and GNG12 NB-specific
genes showed high methylation levels compared to reference
samples in all the NB cases of the validation set (n = 13) (Figure
S2B and S2C). CCND1 showed a clear loss of methylation in 10 of
the 13 independent NBs tested, which is in line with the
proportion of hypoM cases identified by the methylation array
(Figure 2A, 2B and 2C, Figure S2A). EPSTI1 methylation analysis
in the validation series also confirmed the array data (Figure S2D).
Association between DNA methylation and gene
expression
To investigate whether differential DNA methylation in NB is
associated with gene expression, we analyzed published gene
expression data of independent and representative NB tumor sets
[21–23]. Expression data was available for 13 of 23 hyperM and
136 of 328 hypoM NB-specific genes (Table S3A). Five of thirteen
(38.4%) hyperM genes showed lower expression levels as
Figure 1. DNA methylation profiling and identification of differentially methylated genes in NB. A: Unsupervised Principal Component
Analysis (PCA) of array-based DNA methylation data in 21 neuroblastomas (NB) (classified according to INSS Stage), 2 ganglioneuroma (GN), 1
ganglioneuroblastoma (GNB); and normal reference samples: fetal brain (FB) and adrenal gland (AG). B: Venn diagram showing the strategy used to
identify NB-Specific genes. Hypermethylated and hypomethylated genes in NB were determined using three different supervised analyses with
distinct reference samples (FB, AG and GN/GNB). C: Supervised hierarchical cluster analysis of DNA methylation data from NB-specific genes in 21 NB
samples, 2 GN, 1 GNB; and 2 normal reference samples: FB and AG. D: Supervised Principal Component Analysis (PCA) in 21 NB samples, 2 GN, 1 GNB;
and normal reference samples: FB and AG for NB-specific genes.
doi:10.1371/journal.pone.0048401.g001
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compared to reference samples. In contrast, 10 of 136 genes
(7.3%) with lower methylation levels were highly expressed in NB
as compared to reference samples. These results are in line with
previous studies reporting that only a fraction of genes with
promoter hypomethylation show a significant increase in gene
expression, being, possibly, conditioned to specific activation [29–
30].
To validate if differential DNA methylation in NB is associated
with gene expression changes, we analyzed 5 candidate genes by
qRT-PCR in 23 NBs with available RNA (10 cases included in the
methylation array and an independent set of 13 NB samples). In
general, hyperM genes showed lower expression levels in NB
samples compared to reference samples. Likewise, most hypoM
genes showed higher expression levels in the NB tumors with
respect to reference samples, confirming microarray data (data not
shown). CCND1 was found to be highly expressed in all NB
samples, consistent with previous reports [10,31] (Figure 2D).
Biological and functional features of differentially
methylated genes in NB
Differentially methylated genes were functionally characterized
using bioinformatic approaches. A gene ontology (GO) analysis of
genes hypoM in NB allowed the identification of significantly
enriched (p,0.05) functions such as defense response, immune
response, immune system process, response to stimulus and
epidermis development (Table S3B). Due to the small sample
size, gene sets derived from other comparisons did not result in any
significantly enriched GO term.
Most studies in adult tumors have reported that hyperM genes
are enriched in promoters with high CpG content (HCP) and
PRC2 target genes in embryonic stem cell (ESC) [17]. Remark-
ably, in our series, the group of hyperM genes showed a loss for
HCP promoters (21.7% vs. 53.5% in the background, p = 0.072)
and an enrichment for ICP promoters (34.78% vs. 11.68% in the
background, p = 0.012). No significant enrichment for PRC2
targets was observed (13% vs. 9.6% in the background, p = 0.49).
In contrast, hypoM genes showed the previously reported pattern
[17], i.e. they were associated with an increase for low CpG
Figure 2. Methylation and expression data of CCND1. A: Graphical display of the DNA methylation levels of the 17 CpGs measured across the
CCND1 length. The heatmap shows the data from 21 neuroblastoma (NB) and reference samples (2 GN, 1 GNB; 1 FB and 1 AG). Below the heatmap we
show some genomic features of the CCND1 locus (UCSC Genome Browser, data from the hg19 adapted to the hg18) including Transcription Factor
binding sites (TFBS), evolutionary conserved DNAseI hypersensitive domain (DNAseI cluster) and Vertebrate Multiz Aligment, PhastCons Conservation
(Mammal Conservation) and miRNA target sites (TS). B: DNA methylation-specific pyrograms for CCND1. The pyrogram above corresponds to a
neuroblastoma sample whereas the pyrogram below corresponds to a reference sample (FB). Grey shading shows the percentage of methylation
observed for the CpGs analyzed. C: Box-plot for DNA methylation data of CCND1 obtained by bisulfite pyrosequencing in an independent cohort of
13 NB and 2 GN samples and reference samples. D: mRNA expression levels of CCND1 analyzed by qRT-PCR in two NB independent cohorts.
doi:10.1371/journal.pone.0048401.g002
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content promoters (LCP) (68.3% vs. 22.6% in the background,
p,0.001) and a decrease of PRC2 targets (3.3% vs. 9.6% in the
background, p,0.001) (Table S3C).
To determine if differential methylation in NB occurs homo-
geneously throughout the genome, the chromosome distribution of
NB-specific genes was analyzed. Given the small number of
hyperM genes no significant enrichment or grouped tendency was
observed (Table S3D). Conversely, a significant portion of hypoM
genes mapped to chromosomes 1 (48 genes), 17 (25 genes), 19 (58
genes) and 21 (9 genes) (p,0.05 for all) and showed chromosome
specific localization. These genes mapped to specific chromosome
regions 1p36 (20%) and 1q21 (25%), chromosome 17p13 and
17q21 (both 27%), whereas the majority of genes identified on
chromosome 19 were restricted to 19p13 (.70%; 43 of 58), and all
chromosome 21 hypoM genes mapped to 21q22 (9/9).
Dicussion
In the present study, we have analyzed the pattern of differential
methylation in primary NB samples using microarray-based DNA
methylation analysis. Unsupervised PCA showed that DNA
methylation profiles in NB are clearly distinct from those of the
clinically less aggressive GNB and benign GN and the normal
reference samples used in this study (Figure 1A). Differential DNA
methylation analysis using stringent criteria enabled us to identify
DNA methylation changes characteristic of NB tumors. Interest-
ingly, the pattern of hyperM and hypoM was found to be
associated with clinic-biologically relevant subgroups of NB
tumors. Specifically, the DNA methylation pattern of hyperM
genes allowed us to differentiate NBs with diverse MYCN
amplification status. HypoM genes segregated cases according to
age at diagnosis, clustering those with 5 or more years separately
from younger patients (Figure 1D). Supervised DNA methylation
analysis comparing well-known NB clinical subgroups confirmed
the existence of differentially methylated genes between high and
low risk tumors, MYCN A from NA tumors as well as stage 4 from
stage 4S NB. Previous reports analyzing specific candidate genes
have identified hypermethylated genes associated with MYCN
amplification status in NB cell lines and tumors [4], thus
corroborating the existence of subgroup-specific DNA methylation
patterns in NB. However, no consistent DNA methylation
differences were identified when comparing subgroups using the
clinically established prognostic age cut-off of 18 months. In
contrast, in line with the analysis shown in Figure 1D, a consistent
loss of DNA methylation was observed in patients younger than 5
years as compared to older patients and reference samples (Table
S2C). In NB, age at time of diagnosis is a powerful marker of
tumor behavior, and is thus critical in the prognostic evaluation of
this developmental malignancy [32]. Traditionally, patient’s age
has been analyzed as a binary function, with a cut-off point
initially established at 12 months and recently set at a more
optimal prognostic age cut-off of 18 months [32]. However, the
International Neuroblastoma Pathology Classification (the Shi-
mada system) evaluates the prognostic impact of the histological
features of the tumor considering two age cut-offs at time of
diagnosis: 18 months and 5 years [33]. Interestingly, although we
observed age-related DNA methylation patterns recalling these
two age cut-offs, they were more consistent using the 5 years cut-
off.
Overall, we observed that loss of DNA methylation is more
prevalent than promoter hyperM in NB. This is in line with the
well known global hypomethylation of cancer cell DNA, generally
believed to affect repetitive sequences and satellite DNA and to
contribute to the generation of chromosomal instability [2].
Therefore, gene-specific hypomethylation has not been extensively
studied. Interestingly, we observed that hypoM affected genes
relevant to NB pathogenesis such as CCND1. Cyclin D1 is a
regulator subunit of cyclin-dependent kinases required for cell
cycle G1/S transition that has been described highly expressed in
various types of solid tumors as well as in more than 75% of NBs.
The cause of CCND1 overexpression in these tumors is greatly
unknown. High-level amplifications of CCND1 have been reported
only in a small percentage (2%) of NB tumors [10]. Therefore,
mechanisms other than gene amplification seem to be responsible
for increased CCND1 expression [34]. Recently, GATA3, a
transcription factor overexpressed in NB, has been reported to
be implicated in CCND1 overexpression [35]. In this study, we
observed loss of CCND1 gene methylation in more than 70% of the
NB tumors analyzed, associated with high CCND1 expression
levels and absence of gene amplification (data not shown).
Differentially methylated CpGs were not localized in the promoter
region but in the 39 untranslated region (Figure 2A). Interestingly,
based on the data available in the UCSC Genome Browser
(GRCh37/hg19), the 39-UTR of CCND1 is an evolutionary
conserved DNAseI hypersensitive domain highly enriched for
microRNA target sites and Transcription Factor binding sites,
including GATA3, MYC, FOXA1/2 and JUND, among others.
Experimental data supporting the functional role of the 39-UTR
region in the expression of CCND1 have been reported in mantle
cell lymphomas (MCL), where in addition to the fusion of CCND1
gene on chromosome 11 to the immunoglobulin heavy chain
enhancer, the loss of the 39-UTR has been linked to hyper-
proliferative MCL [36]. However, CCND1 rearrangements leading
to loss of the 39-UTR have been observed only in a very small
percentage of NBs [10]. Noteworthy, in our series CCND1 hypoM
occurs in the presence of RASSF1A promoter hyperM. Selective
epigenetic silencing of RASSF1A is a common event in human
cancer, including NB where it has been reported hypermethylated
in .75% of tumors [5,25]. Ras association domain family 1
isoform A is a tumor suppressor that negatively regulates cell
proliferation by inhibiting cyclin D1 protein accumulation through
posttranscriptional mechanisms [37]. RASSF1A hyperM has
previously been inversely associated with cyclin D1 expression
and tumor cell proliferation [38]. It is thus tempting to speculate
that loss of CCND1 gene methylation in the 39-UTR regulatory
region and concomitant hypermethylation of RASSF1A could
represent a potential mechanism underlying CCND1 gene overex-
pression in NB.
Loss of methylation also affected genes with cancer-related
biological functions i.e. SPRR3, previously reported as hypomethy-
lated in cancer, specifically in hepatocellular carcinoma [39].
Overexpression of SPRR3 has been reported to promote breast
and colon cancer proliferation by enhancing p53 degradation via
the AKT and MAPK pathways [40,41]. HypoM also affected genes
reported to stimulate cell proliferation, i.e. BTC, EGF and FGF6.
Betacellulin, member of the EGF family, has recently been
reported to induce proliferation of neural stem cells and prevent
spontaneous differentiation in cell culture via both the EGF
receptor (EGFR) located in NSCs and ErbB4 on neuroblasts [42].
The epidermal growth factor also acts via the EGFR to stimulate
cell proliferation and neoplastic transformation. Fibroblast growth
factor 6, a FGF family member, is implicated in self-renewal and
maintenance of pluripotency of ES and iPS cells [43].
On the other hand, epigenetically suppressed genes included
genes involved in tissue development and differentiation. Among
these, POU2F2, previously described as being hypermethylated in
NB tumors and cell lines, encodes a transcription factor involved
in neuronal differentiation [7,44]. Homeobox D3, member of the
DNA Methylation Profiling in Neuroblastoma
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Hox gene family, has been described associated with the
modulation of cell-adhesive properties during embryonic develop-
ment [45]. Aberrant methylation of HOXD3 has not been
described previously in NB, but has recently been reported as a
novel biomarker of prostate cancer progression together with
RASSF1A, TGF-b and APC [27]. Differentiation-related genes
included IRF6, which encodes a transcription factor that regulates
craniofacial development and epidermal proliferation. IRF6
downregulation has been correlated with promoter methylation
in invasive squamous cell carcinomas [46]. Epithelial membrane
protein-1, a member of the peripheral myelin protein 22 family
expressed in first differentiating neurons, has been described
involved in neural differentiation [47]. Downregulation of EMP1
has been described in squamous cell lung carcinoma suggesting a
potential tumor suppressor function [48].
The functional characterization of differentially methylated
genes revealed that hyperM occurs predominantly at ICP
promoters, while hypoM affects mostly LCP genes, regardless of
the NB subgroup studied. Moreover, the vast majority of changes
of DNA methylation were observed in genes that are not targets of
PcG proteins in ESCs. These findings are in contrast with most
other tumors in which de novo methylation affects predominantly
genes with dense CpG island promoters highly enriched for PcG
targets [14,16,17]. The epigenetic features of NB identified in this
study may be related to the embryonic origin of this developmen-
tal disease, fundamentally different from that of adult cancers.
Additionally, chromosome distribution of NB-specific genes
showed that global DNA hypoM in NB is organized not only at
the functional level but also at spatial level since it significantly
affects specific chromosomes as well as chromosomal regions
previously described to be recurrently altered in NB.
This study provides a genome-wide view of the DNA
methylation landscape in NB. However, it is worth mentioning
that our conclusions are based on a small cohort of cases which
may have led to an overestimation of the data, and that the array
used does not differentiate 5-methylcytosine from 5-hydroxy-
methylcytosine. In spite of these caveats, our findings suggest that
hypoM is a prevalent epigenetic alteration in NB that affects
cancer-related biological functions and specific genes relevant for
NB pathogenesis, such as CCND1. Moreover, hypomethylation
involves chromosomal regions recurrently altered in this malig-
nancy. Our findings also provide evidence for the existence of
DNA methylation profiles characteristic of NB. We identified
specific DNA methylation changes associated with clinical and
genetic features of NB tumors, suggesting altered DNA methyl-
ation patterns as a critical factor for NB tumorigenesis.
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